Circulating mir-125b as a marker predicting chemoresistance in breast cancer

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Wang, Hongjiang ^a   Tan, Guang ^a   Dong, Lei ^a   Cheng, Lei ^a   Li, Kejun ^a   Wang, Zhongyu ^a   Luo, Haifeng ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; MICRORNA; MIR 125B; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG; E2F3 PROTEIN, HUMAN; MIRN125 MICRORNA, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CELL; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROTEIN TARGETING; BLOOD; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; MIDDLE AGED; PAGET NIPPLE DISEASE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; E2F3 TRANSCRIPTION FACTOR; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84859810024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034210     Document Type: Article

References (57)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. He M, Guo Q, Hu G, (2011) Reversed urban-rural differences in breast cancer mortality (China, 2002-2008). Breast Cancer Res Treat 126: 231-234.
3. Chen LP, Cai SM, Fan JX, Li ZT, (1995) PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin) in the treatment of drug-resistant choriocarcinoma. Gynecol Oncol 56: 231-234.
4. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, et al. (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122: 927-939.
5. Tan M, Jing T, Lan KH, Neal CL, Li P, et al. (2002) Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9: 993-1004.
6. Lange C, Yee D, (2011) Killing the second messenger: targeting loss of cell cycle control inendocrine resistant breast cancer. Endocr Relat Cancer 18: C19-24.
7. Senderowicz AM, (2003) Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 52 (Suppl 1): S61-73.
8. Doench JG, Sharp PA, (2004) Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511.
9. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
10. Cho WC, (2007) OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6: 60.
11. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, et al. (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 5: e13735.
12. Schwarzenbach H, Hoon DS, Pantel K, (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437.
13. Yu DC, Li QG, Ding XW, Ding YT, (2011) Circulating MicroRNAs: Potential Biomarkers for Cancer. Int J Mol Sci 12: 2055-2063.
14. Cho WC, (2011) Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. Front Genet 2: 7.
15. Ma L, (2010) Role of miR-10b in breast cancer metastasis. Breast Cancer Res 12: 210.
16. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, et al. (2011) Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30: 2888-2899.
17. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, et al. (2011) miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer. Cancer Res 71: 3552-3562.
18. Kong W, He L, Coppola M, Guo J, Esposito NN, et al. (2010) MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285: 17869-17879.
19. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086.
20. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114-119.
21. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
22. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
23. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, et al. (2009) DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res 37: W273-276.
24. Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L, (2011) Intracellular and extracellular microRNAs in breast cancer. Clin Chem 57: 18-32.
25. Hannafon BN, Sebastiani P, de Las Morenas A, Lu J, Rosenberg CL, (2011) Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 13: R24.
26. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908.
27. Shi XB, Xue L, Yang J, Ma AH, Zhao J, et al. (2007) An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 104: 19983-19988.
28. Tian S, Huang S, Wu S, Guo W, Li J, et al. (2010) MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophys Res Commun 396: 435-439.
29. Xia HF, He TZ, Liu CM, Cui Y, Song PP, et al. (2009) MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem 23: 347-358.
30. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707.
31. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, et al. (2007) Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26: 7590-7595.
32. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, et al. (2009) MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124: 2236-2242.
33. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
34. Ozek NS, Tuna S, Erson-Bensan AE, Severcan F, (2010) Characterization of microRNA-125b expression in MCF7 breast cancer cells by ATR-FTIR spectroscopy. Analyst 135: 3094-3102.
35. Bockmeyer CL, Christgen M, Muller M, Fischer S, Ahrens P, et al. (2011) MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat.
36. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138: 592-603.
37. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, et al. (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496-21507.
38. Gebeshuber CA, Zatloukal K, Martinez J, (2009) miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10: 400-405.
39. Weigel MT, Dowsett M, (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17: R245-262.
40. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, et al. (2003) Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88: 406-412.
41. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, et al. (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9: 5582-5588.
42. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9: 827-836.
43. Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R, (2011) Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 31: 979-984.
44. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, et al. (2011) mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17: 3600-3618.
45. Noonan EJ, Place RF, li LC, (2011) MicroRNAs in Predicting Radiotherapy and Chemotherapy Response. In: Cho WC, editors. MicroRNAs in cancer translational research New York Springer pp. 415-447.
46. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, et al. (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159.
47. Heneghan HM, Miller N, Kerin MJ, (2011) Circulating microRNAs: promising breast cancer Biomarkers. Breast Cancer Res 13: 402.
48. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, et al. (2009) MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23: 862-876.
49. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, et al. (2007) Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282: 1479-1486.
50. Feng N, Xu B, Tao J, Li P, Cheng G, et al. (2011) A miR-125b binding site polymorphism in bone morphogenetic protein membrane receptor type IB gene and prostate cancer risk in China. Mol Biol Rep.
51. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, et al. (2010) MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR. Genes Cancer 1: 62-68.
52. Barbato C, Arisi I, Frizzo ME, Brandi R, Da Sacco L, et al. (2009) Computational challenges in miRNA target predictions: to be or not to be a true target? J Biomed Biotechnol 2009 803069.
53. Iaquinta PJ, Lees JA, (2007) Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 19: 649-657.
54. Polager S, Ginsberg D, (2008) E2F - at the crossroads of life and death. Trends Cell Biol 18: 528-535.
55. Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, et al. (2010) E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol 30: 524-536.
56. Tordai A, Wang J, Andre F, Liedtke C, Yan K, et al. (2008) Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10: R37.
57. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.